The 2019 Heart Rhythm Society scientific sessions: advanced technology in electrophysiology

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

Posição atual:
> This Story

Início de uma sessão ou Registo to rate this News Story
Forward Printable StoryPrint Comment




Cardiology Homepage

Cardiology occupies a unique space in medical informatics Looking at enterprise imaging and informatics through the lens of cardiology at SIIM

MiE showcases cardiac PET scanner, Ancoris, at SNMMI Provides simultaneous 3D cardiac PET perfusion and CFR

AI tool for Alexa and smart devices detects cardiac arrest in sleeping patients Monitors patients for agonal breathing

Mount Sinai surgeons first in NY to perform minimally-invasive heart bypass surgery Only for highly-skilled surgeons for now

New dye helps control 'lighting' for sharper images of heart May help identify early signs of heart disease

Evaluating the cost-effectiveness of AEDs in the U.S. Insights from Dr. Lars W. Andersen on research he conducted and what it should mean for the future of public defibrillators

New machine learning algorithm could decide who is best for heart failure treatment Could help prevent sudden death from heart failure

Philips teams with Medtronic on cryoablation treatment for atrial fibrillation Will form an integrated solution for cryoablation

Varian acquires CyberHeart, enters cardiac radioablation market Emerging technology could benefit treatment of irregular heartbeats

FDA gives thumbs-up for Biofourmis’ RhythmAnalytics AI Platform Provides automated interpretations of cardiac arrhythmias

The 2019 Heart Rhythm Society scientific sessions: advanced technology in electrophysiology

By Lars Thording

The 40th Heart Rhythm Society’s Scientific Sessions brought together manufacturers, clinicians and electrophysiology (EP) leadership to discover and discuss new technology and new techniques in EP procedures. Electrophysiology, a treatment area that addresses the diagnosis and treatment of atrial fibrillation (AF) and similar diagnoses, is expected to grow rapidly in coming years. Due to the high cost of technology involved in EP procedures — and the large volume of procedures expected — this technology conference receives a lot of attention, as the large manufacturers roll out new technologies, clinicians get educated about new opportunities, and providers seek to incorporate them into their operations.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

Electrophysiology is proving to be a treatment area with huge opportunities from the perspective of clinical outcomes. Conversely, there are challenges in terms of patient access and procedure efficacy. New technologies are critically important in increasing patient access, increasing efficacy, and reducing procedure time — but they also represent cost increases on a service line that is dealing with some of the costliest equipment and devices of all service lines in the hospital. Some EP lab managers at the 2019 Heart Rhythm Society conference told me that it is a challenge for them to implement new technologies while still remaining profitable. In fact, one EP lab manager’s primary concern was patient access. To paraphrase the manager, “If I adopt these new technologies, most of which really don’t add quantum leaps in clinical efficacy, is it going to be at the cost of being able to provide the procedures for all the patients that could benefit from them?”

With such concerns in mind, a review of the Heart Rhythm Society’s 40th Annual Scientific Sessions needs to include observations that go beyond technological and clinical advances in the field. Technological progress is only as valuable as the hospital’s ability to adopt such advances while reducing costs, increasing access or reducing procedure time. So while it is easy to be fascinated with the impressive technology in this space, as I walked the exhibition floor in San Francisco, I kept asking the question we all should ask: “Does this produce better patient outcome? And if so, does it also allow me to keep solving the cost equation?” These are very real questions, according to some of the EP lab administrators I met at the conference.

As usual, the exhibition floor was dominated by the great global players in electrophysiology: Biosense Webster (Johnson & Johnson), Abbott, Medtronic, and Boston Scientific. The other half of the exhibition floor was inhabited by a lot of small companies with EP innovations, whose primary goal in attending Heart Rhythm Society is to get acquired by the aforementioned industry giants.

Here are four key takeaways from this year’s conference:

Incremental improvements
There were no big announcements or technology reveals at this year’s conference. Incremental improvements in mapping systems, ablation techniques, and high-resolution mapping were topics discussed in the scientific sessions and in the exhibition areas. In fact, two of the biggest exhibitors and technology leaders in electrophysiology, Biosense Webster and Abbott, were presenting last year’s innovations, the Vizigo bi-directional sheath (Biosense Webster) and the Advisor HD mapping catheter (Abbott). This doesn’t mean they’ve stopped developing new technologies. I fully expect their R&D teams are simply busy at work with the next mapping system or ablation catheters. More to come in the next 12 months, I expect.

  Pages: 1 - 2 - 3 >>

Cardiology Homepage

You Must Be Logged In To Post A Comment